HEALTHCARE
Global Acute Myeloid Leukemia Treatment Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Acute Myeloid Leukemia Treatment Market, By Type (DC regimen, AVD Regimen, VCD regimen), Disease Type (Myeloblastic , Promyelocytic, Myelomonocytic, Monocytic, Erythroleukemia , Megakaryocytic), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), Route of Administration (Oral, Parentral, Others), End User (Hospitals, Homecare, Specialty Centres, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global acute myeloid leukemia treatment market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
Acute Myeloid Leukemia (AML) treatment entails medical procedures targeted at removing leukemic cells and attaining remission in patients. Chemotherapy, radiation therapy, targeted therapy, and stem cell transplantation are the main forms of treatment. These techniques function by either eliminating malignant cells or stopping their spread. The Acute Myeloid Leukemia Treatment Market includes the development, manufacturing, and distribution of various therapies and medications used to treat AML. Pharmaceutical corporations, biotech companies, academic institutions, and healthcare providers are all part of this market. Clinical trials, regulatory clearances, novel treatment commercialization, and developments in immunotherapy and customized medicine are all part of it. The market seeks to provide cutting-edge AML management options, increase patient outcomes, and increase survival rates.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- Rising incidence of acute myeloid leukemia
- Growing geriatric population
RESTRAINTS
- High cost of treatment
- Adverse effects of chemotherapy
OPPORTUNITIES
- Development of novel therapies and drugs
- Expansion in emerging markets
CHALLENGES
- High relapse rate in patients
- Complexity in treatment regimens
SEGMENTATION
- Type
- DC regimen
- AVD Regimen
- VCD regimen
- Disease Type
- Myeloblastic
- Promyelocytic
- Myelomonocytic
- Monocytic
- Erythroleukemia
- Megakaryocytic
- Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormone Therapy
- Others
- Route of Administration
- Oral
- Parentral
- Others
- End User
- Hospitals
- Homecare
- Specialty Centres
- Others
- Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The respective global report is completely customizable specific to regions (North America, Europe, Asia-Pacific, South America, Middle East and Africa), countries, and segments as per the client requirements.
REGIONAL SEGMENTATION
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Pfizer
- Bristol Myers Squibb
- Agios Pharmaceuticals
- Abbvie
- Jazz Pharmaceuticals
- Astellas Pharma
- Pfizer
- Novartis Oncology
- Daiichi Sankyo.
- Bristol Myers Squibb
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Acute Myeloid Leukemia Treatment Market, by Type
- 3.2 Global Acute Myeloid Leukemia Treatment Market, by Disease Type
- 3.3 Global Acute Myeloid Leukemia Treatment Market, by Treatment Type
- 3.4 Global Acute Myeloid Leukemia Treatment Market, by Route of Administration
- 3.5 Global Acute Myeloid Leukemia Treatment Market, by End User
- 3.6 Global Acute Myeloid Leukemia Treatment Market, by Distribution Channel
- 3.7 Global Acute Myeloid Leukemia Treatment Market, by Geography
- 3.8 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Increasing adoption of targeted therapies
- 5.1.2 Advancements in stem cell transplant procedures
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Rising incidence of acute myeloid leukemia
- 5.2.2 Growing geriatric population
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High cost of treatment
- 5.3.2 Adverse effects of chemotherapy
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Development of novel therapies and drugs
- 5.4.2 Expansion in emerging markets
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 High relapse rate in patients
- 5.5.2 Complexity in treatment regimens
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY TYPE
- 6.1 Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Acute Myeloid Leukemia Treatment Market, by Type (2019-2032)
- SECTION 7 - GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY DISEASE TYPE
- 7.1 Disease Type Summary
- 7.2 Market Attractive Index
- 7.3 Global Acute Myeloid Leukemia Treatment Market, by Disease Type (2019-2032)
- SECTION 8 - GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY TREATMENT TYPE
- 8.1 Treatment Type Summary
- 8.2 Market Attractive Index
- 8.3 Global Acute Myeloid Leukemia Treatment Market, by Treatment Type (2019-2032)
- SECTION 9 - GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
- 9.1 Route of Administration Summary
- 9.2 Market Attractive Index
- 9.3 Global Acute Myeloid Leukemia Treatment Market, by Route of Administration (2019-2032)
- SECTION 10 - GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY END USER
- 10.1 End User Summary
- 10.2 Market Attractive Index
- 10.3 Global Acute Myeloid Leukemia Treatment Market, by End User (2019-2032)
- SECTION 11 - GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 11.1 Distribution Channel Summary
- 11.2 Market Attractive Index
- 11.3 Global Acute Myeloid Leukemia Treatment Market, by Distribution Channel (2019-2032)
- SECTION 12 - GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY GEOGRAPHY
- 12.1 Regional Summary
- 12.2 Market Attractive Index
- 12.3 Global Acute Myeloid Leukemia Treatment Market, by Geography (2019-2032)
- SECTION 13 - NORTH AMERICA ACUTE MYELOID LEUKEMIA TREATMENT MARKET
- 13.1 North America Summary
- 13.2 Market Attractive Index
- 13.3 North America Acute Myeloid Leukemia Treatment Market, by Type (2019-2032)
- 13.4 North America Acute Myeloid Leukemia Treatment Market, by Disease Type (2019-2032)
- 13.5 North America Acute Myeloid Leukemia Treatment Market, by Treatment Type (2019-2032)
- 13.6 North America Acute Myeloid Leukemia Treatment Market, by Route of Administration (2019-2032)
- 13.7 North America Acute Myeloid Leukemia Treatment Market, by End User (2019-2032)
- 13.8 North America Acute Myeloid Leukemia Treatment Market, by Distribution Channel (2019-2032)
- 13.9 North America Acute Myeloid Leukemia Treatment Market, by Country (2019-2032)
- 13.9.1 U.S.
- 13.9.2 Canada
- 13.9.3 Mexico
- 13.9.4 Rest of North America
- SECTION 14 - EUROPE ACUTE MYELOID LEUKEMIA TREATMENT MARKET
- 14.1 Europe Summary
- 14.2 Market Attractive Index
- 14.3 Europe Acute Myeloid Leukemia Treatment Market, by Type (2019-2032)
- 14.4 Europe Acute Myeloid Leukemia Treatment Market, by Disease Type (2019-2032)
- 14.5 Europe Acute Myeloid Leukemia Treatment Market, by Treatment Type (2019-2032)
- 14.6 Europe Acute Myeloid Leukemia Treatment Market, by Route of Administration (2019-2032)
- 14.7 Europe Acute Myeloid Leukemia Treatment Market, by End User (2019-2032)
- 14.8 Europe Acute Myeloid Leukemia Treatment Market, by Distribution Channel (2019-2032)
- 14.9 Europe Acute Myeloid Leukemia Treatment Market, by Country (2019-2032)
- 14.9.1 Germany
- 14.9.2 U.K.
- 14.9.3 France
- 14.9.4 Italy
- 14.9.5 Spain
- 14.9.6 Russia
- 14.9.7 The Netherlands
- 14.9.8 Belgium
- 14.9.9 Turkey
- 14.9.10 Rest of Europe
- SECTION 15 - ASIA-PACIFIC ACUTE MYELOID LEUKEMIA TREATMENT MARKET
- 15.1 Asia-Pacific Summary
- 15.2 Market Attractive Index
- 15.3 Asia-Pacific Acute Myeloid Leukemia Treatment Market, by Type (2019-2032)
- 15.4 Asia-Pacific Acute Myeloid Leukemia Treatment Market, by Disease Type (2019-2032)
- 15.5 Asia-Pacific Acute Myeloid Leukemia Treatment Market, by Treatment Type (2019-2032)
- 15.6 Asia-Pacific Acute Myeloid Leukemia Treatment Market, by Route of Administration (2019-2032)
- 15.7 Asia-Pacific Acute Myeloid Leukemia Treatment Market, by End User (2019-2032)
- 15.8 Asia-Pacific Acute Myeloid Leukemia Treatment Market, by Distribution Channel (2019-2032)
- 15.9 Asia-Pacific Acute Myeloid Leukemia Treatment Market, by Country (2019-2032)
- 15.9.1 China
- 15.9.2 India
- 15.9.3 Japan
- 15.9.4 South Korea
- 15.9.5 Singapore
- 15.9.6 Malaysia
- 15.9.7 Australia
- 15.9.8 Thailand
- 15.9.9 Philippines
- 15.9.10 Rest of Asia-Pacific
- SECTION 16 - SOUTH AMERICA ACUTE MYELOID LEUKEMIA TREATMENT MARKET
- 16.1 South America Summary
- 16.2 Market Attractive Index
- 16.3 South America Acute Myeloid Leukemia Treatment Market, by Type (2019-2032)
- 16.4 South America Acute Myeloid Leukemia Treatment Market, by Disease Type (2019-2032)
- 16.5 South America Acute Myeloid Leukemia Treatment Market, by Treatment Type (2019-2032)
- 16.6 South America Acute Myeloid Leukemia Treatment Market, by Route of Administration (2019-2032)
- 16.7 South America Acute Myeloid Leukemia Treatment Market, by End User (2019-2032)
- 16.8 South America Acute Myeloid Leukemia Treatment Market, by Distribution Channel (2019-2032)
- 16.9 South America Acute Myeloid Leukemia Treatment Market, by Country (2019-2032)
- 16.9.1 Brazil
- 16.9.2 Argentina
- 16.9.3 Chile
- 16.9.4 Colombia
- 16.9.5 Rest of South America
- SECTION 17 - MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA TREATMENT MARKET
- 17.1 Middle East and Africa Summary
- 17.2 Market Attractive Index
- 17.3 Middle East and Africa Acute Myeloid Leukemia Treatment Market, by Type (2019-2032)
- 17.4 Middle East and Africa Acute Myeloid Leukemia Treatment Market, by Disease Type (2019-2032)
- 17.5 Middle East and Africa Acute Myeloid Leukemia Treatment Market, by Treatment Type (2019-2032)
- 17.6 Middle East and Africa Acute Myeloid Leukemia Treatment Market, by Route of Administration (2019-2032)
- 17.7 Middle East and Africa Acute Myeloid Leukemia Treatment Market, by End User (2019-2032)
- 17.8 Middle East and Africa Acute Myeloid Leukemia Treatment Market, by Distribution Channel (2019-2032)
- 17.9 Middle East and Africa Acute Myeloid Leukemia Treatment Market, by Country (2019-2032)
- 17.9.1 Kingdom of Saudi Arabia
- 17.9.2 South Africa
- 17.9.3 U.A.E.
- 17.9.4 Egypt
- 17.9.5 Rest of Middle East and Africa
- SECTION 18 - COMPANY SHARE ANALYSIS
- 18.1 Global Acute Myeloid Leukemia Treatment Market, Company Share Analysis
- 18.2 North America Acute Myeloid Leukemia Treatment Market, Company Share Analysis
- 18.3 Europe Acute Myeloid Leukemia Treatment Market, Company Share Analysis
- 18.4 Asia-Pacific Acute Myeloid Leukemia Treatment Market, Company Share Analysis
- SECTION 19 - COMPANY PROFILES
- 19.1 Pfizer
- 19.1.1 Company Snapshot
- 19.1.2 Financial Overview
- 19.1.3 Product Portfolio
- 19.1.4 Recent Developments
- 19.2 Bristol Myers Squibb
- 19.2.1 Company Snapshot
- 19.2.2 Financial Overview
- 19.2.3 Product Portfolio
- 19.2.4 Recent Developments
- 19.3 Agios Pharmaceuticals
- 19.3.1 Company Snapshot
- 19.3.2 Financial Overview
- 19.3.3 Product Portfolio
- 19.3.4 Recent Developments
- 19.4 Abbvie
- 19.4.1 Company Snapshot
- 19.4.2 Financial Overview
- 19.4.3 Product Portfolio
- 19.4.4 Recent Developments
- 19.5 Jazz Pharmaceuticals
- 19.5.1 Company Snapshot
- 19.5.2 Financial Overview
- 19.5.3 Product Portfolio
- 19.5.4 Recent Developments
- 19.6 Astellas Pharma
- 19.6.1 Company Snapshot
- 19.6.2 Financial Overview
- 19.6.3 Product Portfolio
- 19.6.4 Recent Developments
- 19.7 Pfizer
- 19.7.1 Company Snapshot
- 19.7.2 Financial Overview
- 19.7.3 Product Portfolio
- 19.7.4 Recent Developments
- 19.8 Novartis Oncology
- 19.8.1 Company Snapshot
- 19.8.2 Financial Overview
- 19.8.3 Product Portfolio
- 19.8.4 Recent Developments
- 19.9 Daiichi Sankyo.
- 19.9.1 Company Snapshot
- 19.9.2 Financial Overview
- 19.9.3 Product Portfolio
- 19.9.4 Recent Developments
- 19.10 Bristol Myers Squibb
- 19.10.1 Company Snapshot
- 19.10.2 Financial Overview
- 19.10.3 Product Portfolio
- 19.10.4 Recent Developments
- SECTION 20 - RELATED REPORTS
- SECTION 21 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.